The trend of outsourcing research and development work that spurred massive layoffs by pharmaceutical companies and the growth of the contract research organization industry doesn’t seem to be in Allergan’s (NYSE:AGN) playbook. The drug and device maker famous for its anti-wrinkle treatment Botox has opened a 93,000-square-foot R&D facility in New Jersey that is expected […]
Allergan's Lap-Band will now be available for a new group of obese patients. It used to be available only to people with a body mass index of 40 or at least 100 pounds over their ideal weight. Now, patients with a body mass index as low as 30 may be eligible to use the innovative medical device for weight loss. The announcement could increase sales by 51 percent to at least $390 million by 2016.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.